eli lilly Eli Lilly Strikes $2.75 Billion Deal for AI-Developed Drugs Eli Lilly partners with Insilico Medicine in a massive $2.75 billion agreement to bring artificial intelligence-developed drugs to the global market. The deal highlights the growing role of generative AI in accelerating pharmaceutical discovery and development.
eli lilly Eli Lilly Inks $2.75 Billion AI Drug Discovery Deal With Insilico Medicine Eli Lilly partners with Insilico Medicine to license oral therapeutics discovered by artificial intelligence for up to $2.75 billion in milestone payments.
insilico medicine Insilico Medicine Leverages Generative AI to Transform Drug Discovery Pipeline Insilico Medicine utilizes its Pharma.ai suite of generative AI tools to accelerate drug discovery and extend healthy human longevity. The company highlights a robust therapeutic pipeline featuring multiple programs currently in Phase I and Phase II clinical trials.
artificial intelligence AI Platform Achieves Novel Drug Discovery in Under 18 Months Insilico Medicine successfully uses artificial intelligence to discover a new drug target and molecule for idiopathic pulmonary fibrosis, cutting costs and time significantly compared to traditional methods.
insilico medicine AI-Powered Anti-Fibrotic Drug Reaches Clinical Trials in Record 30 Months Insilico Medicine transitions into a clinical-stage biotech company as its AI-discovered and AI-designed anti-fibrotic drug enters Phase I clinical trials. The milestone marks a record-breaking 30-month journey from initial target discovery to human testing.
artificial intelligence AI Breakthroughs in Drug Discovery and Quantum Chemistry Signal Industry Shifts Two recent AI advancements from InSilico Medicine and DeepMind show the technology moving beyond minor efficiencies to disrupt pharmaceutical and materials science industries.